Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Amortization of Deferred Charges (2018 - 2025)

Historic Amortization of Deferred Charges for Tg Therapeutics (TGTX) over the last 8 years, with Q3 2025 value amounting to $304000.0.

  • Tg Therapeutics' Amortization of Deferred Charges fell 2657.0% to $304000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 4787.64%. This contributed to the annual value of $2.0 million for FY2024, which is 1610.6% down from last year.
  • Latest data reveals that Tg Therapeutics reported Amortization of Deferred Charges of $304000.0 as of Q3 2025, which was down 2657.0% from $304000.0 recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' Amortization of Deferred Charges peaked at $639000.0 during Q2 2023, and registered a low of $231000.0 during Q1 2021.
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $461000.0 (2022), whereas its average is $435684.2.
  • Per our database at Business Quant, Tg Therapeutics' Amortization of Deferred Charges skyrocketed by 9956.71% in 2022 and then plummeted by 5258.22% in 2024.
  • Over the past 5 years, Tg Therapeutics' Amortization of Deferred Charges (Quarter) stood at $386000.0 in 2021, then grew by 19.43% to $461000.0 in 2022, then soared by 38.61% to $639000.0 in 2023, then tumbled by 52.58% to $303000.0 in 2024, then rose by 0.33% to $304000.0 in 2025.
  • Its last three reported values are $304000.0 in Q3 2025, $304000.0 for Q2 2025, and $304000.0 during Q1 2025.